Multiple-dose comparative bioavailability study of CCP-07
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2017
At a glance
- Drugs CCP 07 (Primary)
- Indications Common cold
- Focus Pharmacokinetics
- 21 Apr 2017 According to a Vernalis media release, the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-07. The CRL did not raise any concerns with the formulation or pharmacokinetic profile of CCP-07 but did identify outstanding items that need to be addressed prior to the resubmission and approval of the NDA. The company will be working closely with the FDA to resubmit the NDA as quickly as possible.
- 01 Dec 2016 According to a Vernalis media release, is filing NDA with FDA with a PDUFA date of 20 April 2017.
- 14 Apr 2016 According to a Vernalis media release, status changed from recruiting to completed.